title: The effect of caffeic acid phenethyl ester on the prevention of experimentally induced myringosclerosis.
abstract: OBJECTIVE
  Myringosclerosis is a common sequela of ventilation tube insertion for the treatment of the otitis media with effusion. Several antioxidants have been identified to prevent myringosclerosis. The objective of this study was to investigate the effect of caffeic acid phenethyl ester (CAPE) on the prevention of experimentally induced myringosclerosis.
  
  
  METHODS
  Thirty-five Sprague-Dawley rats were unilaterally myringotomized. The rats were divided into four groups randomly: group 1 received no treatment, group 2 received intraperitoneally administered saline and group 3 received intraperitoneally administered CAPE. The tympanic membranes were examined by otomicroscopy on the 15th day after treatment. The membranes were then harvested and evaluated histologically by light microscopy.
  
  
  RESULTS
  The tympanic membranes from group 1 showed extensive myringosclerosis; those from group 2 showed a similar occurrence of myringosclerosis. However, group 3 had a reduced occurrence of myringosclerosis by otomicroscopic evaluation. Under light microscopic examination, the lamina propria of the pars tensa was found to be thicker and more sclerotic in groups 1 and 2 when compared with group 3.
  
  
  CONCLUSIONS
  Systemic treatment with CAPE was found to be effective in the prevention of sclerotic lesions in myringotomized rat tympanic membranes.
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Dongguk University International Hospital, 814 Siksa-Dong, Goyang, Gyeonggi 410-773, South Korea. entsong@empal.com
authors.forename: Jae-Jun
authors.initials: JJ
authors.lastname: Song
authors.forename: Seong Keun
authors.initials: SK
authors.lastname: Kwon
authors.forename: Chang Gun
authors.initials: CG
authors.lastname: Cho
authors.forename: Seok-Won
authors.initials: SW
authors.lastname: Park
mesh_terms: D000818:Animals; D002109:Caffeic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012598:Sclerosis / Q000139:chemically induced / Q000517:prevention & control*; D014432:Tympanic Membrane / Q000187:drug effects* / Q000473:pathology*
chemical_list: D002109:Caffeic Acids; D016328:NF-kappa B; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol